Robbins Farley LLC Abb Vie Inc. Transaction History

Robbins Farley LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$137.6 - $154.97 $91,916 - $103,519	-668 Reduced 81.66%	150 $23,000
Q3 2023 Oct 23, 2023	BUY	$133.59 - $154.65 $20,038 - $23,197	150 Added 22.46%	818 $121,000
Q2 2023 Aug 07, 2023	SELL	$132.51 - $164.9 $22,659 - $28,197	-171 Reduced 20.38%	668 $89,000
Q1 2023 May 04, 2023	BUY	$144.61 - $166.54 $21,691 - $24,981	150 Added 21.77%	839 $133,000
Q4 2022 Feb 06, 2023	BUY	$138.31 - $165.87 $2,904 - $3,483	21 Added 3.14%	689 $111,000
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $6,710 - $7,696	-50 Reduced 6.96%	668 $90,000
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $38,533 - $48,988	-280 Reduced 28.06%	718 $110,000
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $6,598 - $8,187	50 Added 5.27%	998 $162,000
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $100,867 - $114,499	948 New	948 $102,000
Q2 2021 Aug 13, 2021	SELL	$105.21 - $117.21 $99,739 - $111,115	-948 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$102.3 - $112.62 $96,980 - $106,763	948 New	948 $110,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $315B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Robbins Farley LLC, based on Form 13F filings with the SEC.

Stay updated on Robbins Farley LLC with notifications on news.